Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.30)
# 278
Out of 4,814 analysts
79
Total ratings
51.79%
Success rate
16.26%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Initiates: Outperform | $30 | $23.00 | +30.46% | 1 | Mar 12, 2025 | |
| SWTX SpringWorks Therapeutics | Maintains: Outperform | $60 → $65 | $37.78 | +72.05% | 2 | Feb 12, 2025 | |
| MRNA Moderna | Maintains: In-Line | $60 → $50 | $25.19 | +98.49% | 5 | Jan 27, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $33.82 | +47.86% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $13.09 | +281.97% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $98.27 | +27.20% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $58.82 | +78.51% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $549.28 | +113.92% | 5 | Oct 24, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $60.67 | +40.10% | 1 | May 14, 2024 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $175 | $100.10 | +74.83% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $34.97 | +151.64% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $115.29 | +139.40% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $1.58 | +2,115.19% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,520 → $780 | $4.15 | +18,695.18% | 5 | Feb 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $282.64 | -17.92% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.75 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $104.88 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $27.20 | -22.79% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $2.87 | +701.39% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $10.64 | +2,250.73% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $0.50 | +1,900.00% | 1 | Feb 14, 2018 |
Summit Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $30
Current: $23.00
Upside: +30.46%
SpringWorks Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $37.78
Upside: +72.05%
Moderna
Jan 27, 2025
Maintains: In-Line
Price Target: $60 → $50
Current: $25.19
Upside: +98.49%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $33.82
Upside: +47.86%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $13.09
Upside: +281.97%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $98.27
Upside: +27.20%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $58.82
Upside: +78.51%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $549.28
Upside: +113.92%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $60.67
Upside: +40.10%
Neurocrine Biosciences
May 14, 2024
Initiates: Outperform
Price Target: $175
Current: $100.10
Upside: +74.83%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $34.97
Upside: +151.64%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $115.29
Upside: +139.40%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $1.58
Upside: +2,115.19%
Feb 17, 2021
Downgrades: Neutral
Price Target: $1,520 → $780
Current: $4.15
Upside: +18,695.18%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $282.64
Upside: -17.92%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $57.75
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $104.88
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $27.20
Upside: -22.79%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $2.87
Upside: +701.39%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $10.64
Upside: +2,250.73%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $0.50
Upside: +1,900.00%